The cost effectiveness of rapid-acting insulin aspart compared with human insulin in type 2 diabetes patients: an analysis from the Japanese third-party payer perspective

References

• Adler AI, Boyko EJ, Ahroni JH, et al. Risk factors for diabetic peripheral sensory neuropathy. Results of the Seattle Prospective Diabetic Foot Study. Diabetes Care 1997;20:1162-1167
   PubMed Web of Science ®Google Scholar
• Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995;18:258-68
   PubMed Web of Science ®Google Scholar
• Lehto S, Rönnemaa T, Pyörälä K, et al. Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes. Stroke 1996;27:63-68
   PubMed Web of Science ®Google Scholar
• Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316:8233-8238
   Google Scholar
• Standl E, Balletshofer B, Dahl B, et al. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia 1996;39:1540-1545
   PubMed Web of Science ®Google Scholar
• Groeneveld Y, Petri H, Hermans J, et al. Relationship between blood glucose level and mortality in type 2 diabetes mellitus: a systematic review. Diabet Med 1999;16:2-13
   PubMed Web of Science ®Google Scholar
• Wei M, Gaskill SP, Haffner SM, et al. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 1998;21:1167-1172
   PubMed Web of Science ®Google Scholar
• Knuiman MW, Welborn TA, Whittall DE. An analysis of excess mortality rates for persons with non-insulin-dependent diabetes mellitus in Western Australia using the Cox proportional hazards regression model. Am J Epidemiol 1992;135:638-648
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577-1583
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. Diabetes Atlas, 3rd edn. Brussels: International Diabetes Federation, 2006
   Google Scholar
• Bando Y, Kanehara H, Aoki K, et al. Characteristics of undiagnosed diabetes mellitus in a population undergoing health screening in Japan: target populations for efficient screening. Diabetes Res Clin Pract 2009;83:341-346
   Google Scholar
• Neville SE, Boye KS, Montgomery WS, et al. Diabetes in Japan: a review of disease burden and approaches to treatment. Diabetes Metab Res Rev 2009;25:705-716
   PubMed Web of Science ®Google Scholar
• World Health Organization Western Pacific Region. Plan of action for the Western Pacific Declaration on Diabetes 2000-2005. Manila: International Diabetes Foundation – Western Pacific Regional Office, 2001
   Google Scholar
• Kamae I, Kasuga M. [Medical economics of diabetes—consideration of its background and significance.] Medical ASAHI 2003; December: 68-72
   Google Scholar
• Takeda A. [The policy for diabetes of local government]. Nippon Rinsho 2002;60(Suppl 10):608-612
   Google Scholar
• Zhang P, Zhang X, Brown J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:293-301
   PubMed Web of Science ®Google Scholar
• JDFI: Current status, Future Directions. Report of the Juvenile Diabetes Foundation International World Conference on Diabetes Research 1985; Monaco, 1985
   Google Scholar
• Setter SM, Corbett CF, Campbell RK, et al. Insulin aspart: a new rapid-acting insulin analog. Ann Pharmacother 2000;34:1423-1431
   Google Scholar
• Howey DC, Bowsher RR, Brunelle RL, et al. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 1994;43:396-402
   PubMed Web of Science ®Google Scholar
• Torlone E, Fanelli C, Rambotti AM, et al. Pharmacokinetics, pharmacodynamics and glucose counter-regulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28), Pro(B29)] in IDDM. Diabetologia 1994;37:713-720
   PubMed Web of Science ®Google Scholar
• Siebenhofer A, Plank J, Berghold A, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No.: CD003287
   Google Scholar
• Nishimura H, Shintani M, Maeda K, et al. Does multiple injection therapy (MIT) with an ultra-rapid-acting insulin analogue prevent cardiovascular disease in type 2 diabetes? Poster presentation at the 44th Annual Meeting of the European Association for the Study of Diabetes, 2008, Rome, Italy
   Google Scholar
• Stevens RJ, Kothari V, Adler AI, et al.; United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 2001;101:671-679
   Google Scholar
• Appel L, Llinas R. Hypertension and Stroke. Johns Hopkins White Papers, 2007. ISBN 193308748X
   Google Scholar
• Clarke PM, Gray AM, Briggs A, et al.; UK Prospective Diabetes Study (UKDPS) Group. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47:1747-1759
   Google Scholar
• World Health Organization. Japanese life tables. Available at http://www.who.int/whosis/database/life_tables/life_tables.cfm [last accessed 8/7/2009]
   Google Scholar
• Inomata T, Izumi T, Kobayashi M. Cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan. Circ J 2004;68:35-40
   Google Scholar
• Saito I, Kobayashi M, Matsushita Y, et al. Cost-utility analysis of antihypertensive combination therapy in Japan by a Monte Carlo simulation model. Hypertens Res 2008;31:1373-1383
   PubMed Web of Science ®Google Scholar
• Miyagawa T, Arakawa I, Shiragami M, et al. Cost-effectiveness of including salmeterol in asthma therapy in a primary care setting in Japan. Yakugaku Zasshi 2006;126:51-59
   Google Scholar
• Tsutani K, Igarashi A, Fujikawa K, et al. A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan. Intern Med 2007;46:157-162
   PubMed Web of Science ®Google Scholar
• Babazono A, Miyazaki M, Imatoh T, et al. Effects of the increase in co-payments from 20 to 30 percent on the compliance rate of patients with hypertension or diabetes mellitus in the Employed Health Insurance System. Int J Technol Assess Health Care 2005;21:228-233
   Google Scholar
• Reviriego J, Gomis R, Marañés JP, et al. Cost of severe hypoglycaemia in patients with type 1 diabetes in Spain and the cost-effectiveness of insulin lispro compared with regular human insulin in preventing severe hypoglycaemia. Int J Clin Pract 2008;62:1026-1032
   PubMed Web of Science ®Google Scholar
• Citibank N.A. via Google Finance. EUR to JPY 2008 mid-year exchange rate. http://www.google.com/finance?chdet=1215126000000&chddm=27620&q=CURRENCY:EURJPY&ntsp=0. Last accessed October 30, 2010
   Google Scholar
• Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22:340-349
   PubMed Web of Science ®Google Scholar
• Seto TB, Taira DA, Berezin R, et al. Percutaneous coronary revascularization in elderly patients: Impact on functional status and quality of life. Ann Intern Med 2000;132:955-958
   PubMed Web of Science ®Google Scholar
• Rumsfeld JS, Magid DJ, Plomondon ME, et al. Department of Veterans Affairs Angina With Extremely Serious Operative Mortality (AWESOME) Investigators. Health-related quality of life after percutaneous coronary intervention versus coronary bypass surgery in high-risk patients with medically refractory ischemia. J Am Coll Cardiol 2003;41:1732-1738
   PubMed Web of Science ®Google Scholar
• Loponen P, Luther M, Korpilahti K, et al. HRQoL after coronary artery bypass grafting and percutaneous coronary intervention for stable angina. Scand Cardiovasc J 2009;43:94-99
   PubMed Web of Science ®Google Scholar
• Davis RE, Wittrup-Jensen KU, Peters JR, et al. The impact on health-related quality of life (EQ-5D index) in people with type 1 diabetes who experience severe hypoglycemia. Diabetologia 2005;48 Suppl: A3. (EASD abstract and poster)
   Google Scholar
• Shiroiwa T, Sung YK, Fukuda T, et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 2010;19:422-437
   PubMed Web of Science ®Google Scholar
• Gallagher A, Home PD. The effect of improved post-prandial blood glucose control on post-prandial metabolism and markers of vascular risk in people with type 2 diabetes. Diabetes Res Clin Pract 2005;67:196-203
   PubMed Web of Science ®Google Scholar
• Sekikawa A, Kuller LH, Ueshima H, et al. Coronary heart disease mortality trends in men in the post World War II birth cohorts aged 35-44 in Japan, South Korea and Taiwan compared with the United States. Int J Epidemiol 1999;28:1044-1049
   Google Scholar
• Iwamoto Y, Akanuma Y, Niimi H, et al. Comparison between insulin aspart and soluble human insulin in type 1 diabetes (IDDM) patients treated with basal-bolus insulin therapy -- Phase III clinical trial in Japan. J Japan Diabet Soc 2001;44:799-811
   Google Scholar
• Haffner SM. The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease. Endocr Rev 1998;19:583-592
   PubMed Web of Science ®Google Scholar
• Bonora E. Postprandial peaks as a risk factor for cardiovascular disease: epidemiological perspectives. Int J Clin Pract Suppl 2002;129:5-11
   Google Scholar
• Temelkova-Kurktschiev TS, Koehler C, Henkel E, et al. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 2000;23:1830-1834
   PubMed Web of Science ®Google Scholar
• DECODE Study Group, European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003;26:688-696
   PubMed Web of Science ®Google Scholar
• Stentz FB, Umpierrez GE, Cuervo R, et al. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes 2004;53:2079-2086
   PubMed Web of Science ®Google Scholar
• Willan AR, O'Brien BJ. Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data. Health Econ 1999;8:203-211
   PubMed Web of Science ®Google Scholar